surmount-1 tirzepatide Trial Summary: What Actually Showed Tirzepatide SURMOUNT-1 three year efficacy

Trends Endocrinol metabolism: TEM (2018) 29(6):38999

Regular monitoring should include: Blood pressure measurements at follow-up visits Assessment of heart rate and rhythm Evaluation for symptoms of cardiovascular decompensation Periodic review of cardiovascular risk factors and comorbidities Patients with heart failure require special consideration

Blood glucose control timeline: Days 17: Initial postprandial (after-meal) glucose improvements become apparent, particularly reduced glucose spikes after eating Weeks 24: Fasting glucose levels begin to decrease

Common Side Effect to Watch: GI upset nausea, diarrhea, stomach cramps